NCT06386874
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Poor accrual Show 6 more changesShow less
- Eligibility criteria expanded, about 25 words
- Final enrollment: 62 participants (planned 122)
- Primary completion date changed from estimate of Jul 2026 to Dec 26, 2025
- Study completion date changed from estimate of Oct 2026 to Apr 7, 2026
- Secondary endpoints: details revised at 3 of 16 entries
- Site details revised at 14 of 14 sites
- Minor Site details revised at 1 of 14 sitesv5
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
- Study sites: 1 to 14
- Start date changed from estimate of Aug 2024 to Aug 20, 2024
- Interventions: BQ 3.0 (Device), BQ 3.0 system (Device) to Q Therapeutic System (BQ 3.0) - Active (Device), Q Therapeutic System (BQ 3.0) - Sham (Device)
- Secondary endpoints: 9 to 16
- Study description expanded, about 435 words
- Minor Start date: Jul 2024 to Aug 2024v3
Notable Lead sponsor: [Redacted] to BrainQ Technologies Ltd.v2 Show 5 more changesShow less
- Trial status: Withheld to Not Yet Recruiting
- Primary completion date: Jul 2026
- Study completion date: Oct 2026
- Start date: Jul 2024
- Study title shortened, about 2 words
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (16)
Show 11 moreShow less
Arms and interventions
Q Therapeutic System (BQ 3.0) sham stimulation group: Device used: Q Therapeutic System (BQ 3.0) In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 3.0 (frequency and intensity parameters will be set to zero so that no stimulation is delivered) including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
Q Therapeutic System (BQ 3.0) active stimulation group: Device used: Q Therapeutic System (BQ 3.0) In Stage 1: 45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with the BQ 3.0 (frequency and intensity parameters will be set to 1-100 Hz.; 0.1-1.0 G), including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
Devices: Q Therapeutic System (BQ 3.0) - Sham, Q Therapeutic System (BQ 3.0) - Active
Sites
14 sites in 1 country